At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11 enrolled
Drug / intervention
Magnesium supplement (magnesium hydroxide/ -oxide) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Daily Mablet-treatment of Patients With COPD
In Brief
A clinical study evaluating Magnesium supplement (magnesium hydroxide/ -oxide) and Placebo for COPD. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease. The aim of this part of the project is to study the effect of a daily magnesium supplement for COPD-patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesDenmark
CollaboratorsGunnar Kjems APS, Aarhus University Hospital
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartOct 2010
Primary CompletionMar 2013
TodayJul 2026
First PostedMay 7, 2010
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.2 years ago
Interventions
Magnesium supplement (magnesium hydroxide/ -oxide)dietary
3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
Placebodietary
3 tablets of placebo daily for 12 weeks